Kimyrsa

DRUG2 trials

Sponsors

Melinta Therapeutics, Inc., Melinta Therapeutics, LLC

Conditions

Acute Bacterial Skin and Skin Structure Infection

Phase 1

Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients

CompletedNCT03873987

Melinta Therapeutics, Inc.Acute Bacterial Skin and Skin Structure Infection

Start: 2019-07-16End: 2019-09-04Updated: 2021-04-13

Phase 2

Study to Evaluate the Safety of Intravenous Oritavancin for the Treatment of Children With Skin Infections

CompletedNCT05599295

Melinta Therapeutics, LLCAcute Bacterial Skin and Skin Structure Infection

Start: 2023-06-15End: 2025-11-20Updated: 2025-11-25